Craft
  • Home
  •  / Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

Revenue

$351.4 M

FY, 2021

Market Capitalization

$3.1 B

2022-09-20

Ultragenyx Pharmaceutical Summary

Company summary

Overview
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. It is creating an improved model for successful rare disease drug development that increases efficiency and effectiveness by changing the way the process is organized and conducted. The Company believes that it can deliver significant value to its patients by building a diverse and high quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.
Type
Public
Founded
2010
HQ
Novato, CA, US | view all locations
Website
http://www.ultragenyx.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Daniel G. Welch, Chairman

    • Emil D. Kakkis

      Emil D. Kakkis, Founder, President and Chief Executive Office

      • Erik Harris

        Erik Harris, Chief Commercial Officer and Executive Vice President

        • Camille L. Bedrosian

          Camille L. Bedrosian, Chief Medical Officer and Executive Vice President

          LocationsView all

          1 location detected

          • Novato, CA HQ

            United States

            60 Leveroni Ct

          Ultragenyx Pharmaceutical Financials

          Summary financials

          Footer menu